Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial.

Trial Profile

Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Anaemia; Beta-thalassaemia; Haemochromatosis; Sideroblastic anaemia
  • Focus Therapeutic Use
  • Acronyms PPI Shine Again
  • Most Recent Events

    • 06 Nov 2019 According to trial design released at 61st Annual Meeting and Exposition of the American Society of Hematology, Results are expected Q3 2020. The trial is funded by ZonMW, The Netherlands Organization for Health and Research Development, and by the Innovatiefonds Zorgverzekeraars.
    • 06 Nov 2019 Trial design released at 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top